Should I Buy CLLS? CLLS 2026 Analysis

Should You Buy Cellectis SA (CLLS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.410

1 Day change

0.89%

52 Week Range

5.480

Analysis Updated At

2026/04/03

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Cellectis SA (CLLS) is not a strong buy for a beginner, long-term investor at the moment. The technical indicators are mixed, with bearish moving averages and neutral RSI, while the options data suggests low trading sentiment. Additionally, there are no significant positive catalysts, news, or financial performance data to support a strong buy decision. Given the lack of recent trading signals and the absence of influential activity or strong growth trends, holding off on investment is recommended until more favorable conditions emerge.

Technical Analysis

The MACD histogram is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral at 58.807, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are Pivot: 3.253, R1: 3.448, S1: 3.058, R2: 3.568, S2: 2.938.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate limited trading sentiment, and the implied volatility is high at 484.86, suggesting significant uncertainty.

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news, congress trading data, or influential figure activity.

Neutral/Negative Catalysts

Bearish moving averages, lack of significant trading trends from hedge funds or insiders, and no recent financial performance data.

Financial Performance

No financial performance data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available.

4 Analyst Rating

Wall Street analysts forecast CLLS stock price to rise

2 Buy

2 Hold

0 Sell

Moderate Buy

Current: 3.380

Low

Averages

High

Current: 3.380

Low

Averages

High

Clear Street

Bill Maughan

initiated

AI Analysis

2025-12-22

Reason

Clear Street

Bill Maughan

Price Target

AI Analysis

2025-12-22

initiated

Reason

Clear Street analyst Bill Maughan initiated coverage of Cellectis with a Buy rating and $9 price target. Cellectis has produced "strong" efficacy data from its initial program, lasme-cel in acute lymphoblastic leukemia, and "an encouraging initial efficacy signal" from eti-cel in non-hodgkin's lymphoma, which the firm believes positions Cellectis well to be among the first companies to bring an allogenic CAR-T product for the treatment of hematological cancers to market.

Wells Fargo

Nick Abbott

Equal Weight

maintain

$3 -> $4

2025-10-20

Reason

Wells Fargo

Nick Abbott

Price Target

$3 -> $4

2025-10-20

maintain

Equal Weight

Reason

Wells Fargo analyst Nick Abbott raised the firm's price target on Cellectis to $4 from $3 and keeps an Equal Weight rating on the shares. The firm says new data from DL3 of ALL study are promising, with high CR/CRi & MRD-ve rates in patients with few options. Clarity on regulatory path is also positive, Wells adds. Pivotal Phase 2 execution is now key, with first data Q4 2026 and BLA filing in the second half of 2028, along with clarity on market size/opportunity.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CLLS

Unlock Now

CLLS Should I Buy

CLLS Should I Buy

Should You Buy Cellectis SA (CLLS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch